Adaptive Perfusion: A Novel In Vitro Drug Release Testing Method for Complex Drug Products
Download the Abstract (PDF - 122KB)
Drug in vitro release testing (IVRT), also called dissolution testing, is used to measure the extent and rate of drug release from tablets, capsules, ointments, and other formulations. Dissolution testing is necessary in the pharmaceutical industry during drug development to create the optimal drug release profile, and during drug manufacturing as an essential quality control (QC) test to assess batch-to-batch consistency.
Currently available IVRT methods for complex drug formulations rely on diffusion processes using dialysis membranes and have numerous limitations such as lengthy testing times, the inability to analyze the percentage of drug remaining, and dependency on nonadjustable conditions such as concentration gradient and surface area. These limitations make measuring the release of drugs from complex drug products including emulsions, micelles, suspensions, liposomes, and drug-protein complexes analytically challenging.
Adaptive Perfusion (AP) is a new IVRT system that overcomes the limitations of conventional IVRT methods and allows drug release from complex particulate formulations to be investigated. This technique operates based on the principle of the pressure-driven separation by tangential flow filtration (TFF) rather than the rate-limiting passive membrane diffusion. Unique features of AP are the pressure gradient and the size-based separation that can be adjusted based on the type of formulation being analyzed, thus overcoming the limitations encountered in other IVRT methods.
|Potential Commercial Applications||Competitive Advantages|
Development Stage: In vitro data, prototype
Inventors: Xiaoming Xu, Deval Patel, and Ying Zhang
Publications: Patel, et. al. Adaptive Perfusion: An in vitro release test (IVRT) for complex drug products. J Control Release. 2021 Mar 23;333:65-75. PMID: 33766693
U.S. provisional application 63/128,505 was filed December 21, 2020
PCT application PCT/US2021/064387 was filed December 20, 2021
Product Area: drug development, drug formulations, drug manufacturing, drug production, quality control, drug delivery
FDA Reference No: E-2020-025
FDA Technology Transfer Program